Jones Curtis G, Pechauer Shannon M, Curtis Brian R, Bougie Daniel W, Irani Mehraboon S, Dhakal Binod, Pierce Brenda, Aster Richard H, Padmanabhan Anand
Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, WI.
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI.
Chest. 2017 Oct;152(4):e77-e80. doi: 10.1016/j.chest.2017.06.001.
Heparin-induced thrombocytopenia (HIT) is a dangerous complication of heparin therapy. HIT diagnosis is established by recognizing thrombocytopenia and/or thrombosis in an affected patient and from the results of serological tests such as the platelet factor 4 (PF4)/heparin immunoassay (PF4 ELISA) and serotonin release assay (SRA). Recent studies suggest that HIT antibodies activate platelets by recognizing PF4 in a complex with platelet glycosaminoglycans (and/or polyphosphates) and that an assay based on this principle, the PF4-dependent P-selectin expression assay (PEA), may be even more accurate than the SRA for HIT diagnosis. Here, we demonstrate that the PEA detected pathogenic antibodies before the SRA became positive in two patients with HIT studied serially, in one case even before seropositivity in the PF4 ELISA. In one of the patients treated with plasma exchange, persistent dissociation between the PEA and SRA test results was observed. These results support a role for the PEA in early HIT diagnosis.
肝素诱导的血小板减少症(HIT)是肝素治疗的一种危险并发症。HIT的诊断是通过识别受影响患者的血小板减少和/或血栓形成以及血清学检测结果来确定的,如血小板因子4(PF4)/肝素免疫测定(PF4 ELISA)和5-羟色胺释放试验(SRA)。最近的研究表明,HIT抗体通过识别与血小板糖胺聚糖(和/或多磷酸盐)结合的PF4来激活血小板,基于这一原理的检测方法,即PF4依赖性P-选择素表达试验(PEA),在HIT诊断中可能比SRA更准确。在此,我们证明,在对两名接受连续研究的HIT患者进行检测时,PEA在SRA呈阳性之前就检测到了致病性抗体,在一例患者中甚至在PF4 ELISA血清学阳性之前就检测到了。在接受血浆置换治疗的一名患者中,观察到PEA和SRA检测结果持续不一致。这些结果支持了PEA在HIT早期诊断中的作用。